Clinical Trials Directory

Trials / Unknown

UnknownNCT03586193

Pars Plana Vitrectomy Alone in the Treatment of Macular Schisis in High Myopic Eyes

Application of Pars Plana Vitrectomy in the Treatment of Macular Schisis in High Myopic Eyes

Status
Unknown
Phase
Study type
Observational
Enrollment
40 (estimated)
Sponsor
Aier School of Ophthalmology, Central South University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

High myopic schisis (HMF) has the clinical feature of separation between retinal layers. It is sometimes accompanied with foveal retinal detachment, macular lamellar hole, epiretinal membrane and vitreous retraction. HMF may develop to macular hole, macular detachment and will damage the visual function. Pars plana vitrectomy (PPV) is a commonly used surgery in the treatment of HMF. PPV together with internal limiting membrane (ILM) peeling and long-term gas tamponade was reported to be safe and effective. But nowadays there was no available long-term gas in our country. Also, whether ILM peeling is necessary remains controversial, Indole cyanine green (ICG)was proved to have potential toxicity to the retina and the ILM peeling has the risk of causing secondary macular hole. We propose to make a prospective nonrandomized controlled study to evaluate the safety and efficiency of using PPV alone in the treatment of HMF.

Conditions

Interventions

TypeNameDescription
PROCEDUREPars plana vitrectomypars plana vitrectomy without ICG staining and ILM peeling

Timeline

Start date
2018-05-01
Primary completion
2018-12-31
Completion
2019-05-31
First posted
2018-07-13
Last updated
2018-07-13

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03586193. Inclusion in this directory is not an endorsement.